The Federal Authorities has as we speak introduced that medicines on the Pharmaceutical Advantages Scheme (PBS) will value not more than $25 from 1 January 2026.
In a pre-election dedication that has been matched by the Federal Opposition, the utmost value of a PBS prescription will drop from $31.60 to $25.
Diabetes Australia Group CEO Justine Cain welcomed the announcement saying individuals taking diabetes medicines listed on the PBS will profit from this value of residing reduction.
“An individual’s financial institution stability or postcode shouldn’t be a barrier to good well being. We should guarantee medicines are reasonably priced for individuals who want them.
“Final yr Diabetes Australia undertook a price of residing survey which confirmed that for 61% of individuals, the price of diabetes medicines and applied sciences was their best problem.
“Decreasing the price of PBS medicines will assist our neighborhood with the appreciable pressure of residing with a power situation,” Ms Cain mentioned.
Diabetes medicines included within the worth change embody Metformin, Semaglutide, Empagliflozin, Dapagliflozin, and Empagliflozin with metformin.
The Federal Authorities mentioned the funding will value $689 million over 4 years and the adjustments would come into impact on 1 January 2026 in step with common indexation.
